Table 2.
Characteristics of patients aged 50 years and older
| No respiratory condition (n=47 398) | Asthma (n=5918) | Chronic pulmonary disease, no asthma (n=10 266) | Asthma and chronic pulmonary disease (n=2071) | ||
|---|---|---|---|---|---|
| Demographic characteristics | |||||
| Mean age, years | 75·7 (12·5) | 72·1 (12·8) | 77·8 (9·6) | 76·1 (10·6) | |
| Age group, years | |||||
| 50–69 | 15 523 (32·8%) | 2625 (44·4%) | 2008 (19·6%) | 560 (27·0%) | |
| 70–80 | 11 323 (23·9%) | 1373 (23·2%) | 3638 (35·4%) | 690 (33·3%) | |
| >80 | 20 552 (43·4%) | 1920 (32·4%) | 4620 (45·0%) | 821 (39·6%) | |
| Sex at birth | |||||
| Female | 19 977 (42·1%) | 3289 (55·6%) | 4195 (40·9%) | 1090 (52·6%) | |
| Male | 27 291 (57·6%) | 2618 (44·2%) | 6053 (59·0%) | 974 (47·0%) | |
| Data missing | 130 (0·3%) | 11 (0·2%) | 18 (0·2%) | 7 (0·3%) | |
| Ethnicity | |||||
| Asian | 2255 (4·8%) | 377 (6·4%) | 184 (1·8%) | 67 (3·2%) | |
| Black | 1565 (3·3%) | 187 (3·2%) | 105 (1·0%) | 30 (1·4%) | |
| White | 35 481 (74·9%) | 4431 (74·9%) | 8738 (85·1%) | 1710 (82·6%) | |
| Other | 2620 (5·5%) | 340 (5·7%) | 349 (3·4%) | 83 (4·0%) | |
| Data missing | 5477 (11·6%) | 583 (9·9%) | 890 (8·7%) | 181 (8·7%) | |
| Deprivation (IMD quintile) | |||||
| 1 | 8586 (18·1%) | 1026 (17·3%) | 1503 (14·6%) | 258 (12·5%) | |
| 2 | 9138 (19·3%) | 1096 (18·5%) | 1843 (18·0%) | 366 (17·7%) | |
| 3 | 8906 (18·8%) | 1080 (18·2%) | 1766 (17·2%) | 350 (16·9%) | |
| 4 | 9413 (19·9%) | 1196 (20·2%) | 2150 (20·9%) | 431 (20·8%) | |
| 5 | 11 336 (23·9%) | 1519 (25·7%) | 3001 (29·2%) | 666 (32·2%) | |
| Data missing | 19 (<0·1%) | 1 (<0·1%) | 3 (<0·1%) | 0 | |
| Smoking | |||||
| Never smoked | 15 661 (33·0%) | 2352 (39·7%) | 1661 (16·2%) | 420 (20·3%) | |
| Former smoker | 9114 (19·2%) | 1226 (20·7%) | 4088 (39·8%) | 800 (38·6%) | |
| Current smoker | 1707 (3·6%) | 197 (3·3%) | 1116 (10·9%) | 192 (9·3%) | |
| Data missing | 20 916 (44·1%) | 2143 (36·2%) | 3401 (33·1%) | 659 (31·8%) | |
| Clinical characteristics | |||||
| Obesity | |||||
| No | 35 123 (74·1%) | 4136 (69·9%) | 7584 (73·9%) | 1425 (68·8%) | |
| Yes | 3872 (8·2%) | 876 (14·8%) | 955 (9·3%) | 304 (14·7%) | |
| Data missing | 8403 (17·7%) | 906 (15·3%) | 1727 (16·8%) | 342 (16·5%) | |
| Chronic cardiac disease | |||||
| No | 28 755 (60·7%) | 3836 (64·8%) | 4964 (48·4%) | 1039 (50·2%) | |
| Yes | 15 232 (32·1%) | 1816 (30·7%) | 4876 (47·5%) | 945 (45·6%) | |
| Data missing | 3411 (7·2%) | 266 (4·5%) | 426 (4·1%) | 87 (4·2%) | |
| Malignant neoplasm | |||||
| No | 38 274 (80·8%) | 5131 (86·7%) | 8302 (80·9%) | 1717 (82·9%) | |
| Yes | 5036 (10·6%) | 441 (7·5%) | 1336 (13·0%) | 229 (11·1%) | |
| Data missing | 4088 (8·6%) | 346 (5·8%) | 628 (6·1%) | 125 (6·0%) | |
| Chronic kidney disease | |||||
| No | 35 149 (74·2%) | 4689 (79·2%) | 7464 (72·7%) | 1493 (72·1%) | |
| Yes | 8530 (18·0%) | 911 (15·4%) | 2264 (22·1%) | 468 (22·6%) | |
| Data missing | 3719 (7·8%) | 318 (5·4%) | 538 (5·2%) | 110 (5·3%) | |
| Diabetes with complications | |||||
| No | 34 606 (73·0%) | 4348 (73·5%) | 7801 (76·0%) | 1501 (72·5%) | |
| Yes | 7436 (15·7%) | 1056 (17·8%) | 1568 (15·3%) | 388 (18·7%) | |
| Data missing | 5356 (11·3%) | 514 (8·7%) | 897 (8·7%) | 182 (8·8%) | |
| Diabetes without complications | |||||
| No | 38 457 (81·1%) | 4988 (84·3%) | 8568 (83·5%) | 1703 (82·2%) | |
| Yes | 3489 (7·4%) | 394 (6·7%) | 785 (7·6%) | 188 (9·1%) | |
| Data missing | 5452 (11·5%) | 536 (9·1%) | 913 (8·9%) | 180 (8·7%) | |
| Mild liver disease | |||||
| No | 42 430 (89·5%) | 5471 (92·4%) | 9400 (91·6%) | 1892 (91·4%) | |
| Yes | 638 (1·3%) | 90 (1·5%) | 184 (1·8%) | 40 (1·9%) | |
| Data missing | 4330 (9·1%) | 357 (6·0%) | 682 (6·6%) | 139 (6·7%) | |
| Moderate or severe liver disease | |||||
| No | 42 365 (89·4%) | 5476 (92·5%) | 9373 (91·3%) | 1886 (91·1%) | |
| Yes | 814 (1·7%) | 93 (1·6%) | 237 (2·3%) | 55 (2·7%) | |
| Data missing | 4219 (8·9%) | 349 (5·9%) | 656 (6·4%) | 130 (6·3%) | |
| Chronic neurological disorder | |||||
| No | 37 113 (78·3%) | 4969 (84·0%) | 8376 (81·6%) | 1703 (82·2%) | |
| Yes | 6323 (13·3%) | 621 (10·5%) | 1297 (12·6%) | 234 (11·3%) | |
| Data missing | 3962 (8·4%) | 328 (5·5%) | 593 (5·8%) | 134 (6·5%) | |
| Chronic haematological disease | |||||
| No | 41 246 (87·0%) | 5344 (90·3%) | 9159 (89·2%) | 1832 (88·5%) | |
| Yes | 1991 (4·2%) | 222 (3·8%) | 482 (4·7%) | 118 (5·7%) | |
| Data missing | 4161 (8·8%) | 352 (5·9%) | 625 (6·1%) | 121 (5·8%) | |
| Rheumatological disorder | |||||
| No | 37 847 (79·8%) | 4790 (80·9%) | 8266 (80·5%) | 1598 (77·2%) | |
| Yes | 5217 (11·0%) | 778 (13·1%) | 1377 (13·4%) | 353 (17·0%) | |
| Data missing | 4334 (9·1%) | 350 (5·9%) | 623 (6·1%) | 120 (5·8%) | |
| Medication characteristics | |||||
| Medication | |||||
| Reported | 47 398 (100·0%) | 5745 (97·1%) | 10 033 (97·7%) | 2033 (98·2%) | |
| Data missing | 0 | 173 (2·9%) | 233 (2·3%) | 38 (1·8%) | |
| Salbutamol | 1805 (3·8%) | 3077 (52·0%) | 4543 (44·3%) | 1223 (59·1%) | |
| ICS components | |||||
| No steroid | 46 182 (97·4%) | 2264 (38·3%) | 6024 (58·7%) | 661 (31·9%) | |
| Beclometasone | 712 (1·5%) | 2000 (33·8%) | 2195 (21·4%) | 738 (35·6%) | |
| Budesonide | 153 (0·3%) | 578 (9·8%) | 421 (4·1%) | 192 (9·3%) | |
| Ciclesonide | 26 (0·1%) | 12 (0·2%) | 19 (0·2%) | 12 (0·6%) | |
| Fluticasone | 325 (0·7%) | 891 (15·1%) | 1374 (13·4%) | 431 (20·8%) | |
| Data missing | 0 | 173 (2·9%) | 233 (2·3%) | 37 (1·8%) | |
| LABA | 355 (0·7%) | 1583 (26·7%) | 1704 (16·6%) | 676 (32·6%) | |
| LAMA | 312 (0·7%) | 404 (6·8%) | 1954 (19·0%) | 450 (21·7%) | |
| LTRAs | 45 (0·1%) | 524 (8·9%) | 165 (1·6%) | 227 (11·0%) | |
| Theophylline | 14 (0·0%) | 88 (1·5%) | 310 (3·0%) | 103 (5·0%) | |
| Oral corticosteroids | |||||
| No | 44 440 (93·8%) | 5434 (91·8%) | 9132 (89·0%) | 1794 (86·6%) | |
| Yes | 1371 (2·9%) | 436 (7·4%) | 1051 (10·2%) | 261 (12·6%) | |
| Data missing | 1587 (3·3%) | 48 (0·8%) | 83 (0·8%) | 16 (0·8%) | |
Data are n (%) or mean (SD), unless otherwise indicated. IMD=Index of Multiple Deprivation. ICS=inhaled corticosteroid. LABA=long-acting β-agonist. LAMA=long-acting muscarinic antagonist. LTRA=leukotriene receptor antagonist.